|
Jun 20
|
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
|
|
Jun 18
|
Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven?
|
|
Jun 18
|
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
|
|
Jun 16
|
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
|
|
Feb 16
|
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
|
|
Feb 11
|
Why Axsome Therapeutics (AXSM) Is Advancing Today
|
|
Feb 11
|
Why Axsome Therapeutics Stock Is Soaring Today
|
|
Feb 11
|
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
|
|
Feb 11
|
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
|
|
Feb 10
|
Why Axsome Therapeutics Stock Is Skyrocketing Today
|
|
Feb 10
|
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
|
|
Feb 10
|
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
|
|
Dec 31
|
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
|
|
Dec 30
|
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
|
|
Dec 30
|
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
|
|
Aug 27
|
Axsome Therapeutics to Participate in Investor Conferences in September
|
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 19
|
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week
|
|
May 13
|
15 Most Depressed States in the US
|